Health Condition 1: null- Essential hypertension Stage 1
Conditions
Interventions
Intervention1: Telmisartan: Class - Angiotensin Receptor Blocker.Dose - as per physicians discretion to control hypertension.
Frequency - once daily.
Route of administration - Oral.
Total duration of
Sponsors
Lady Hardinge Medical College
Eligibility
Inclusion criteria
Inclusion criteria: Treatment naÑ?ve essential hypertension stage 1 patients.
Exclusion criteria
Exclusion criteria: 1.Patient with comorbid type 1 or type 2 diabetes mellitus. 2.Patients taking statins or other lipid lowering agents, supplemental vitamins and antioxidants. 3.Serum triglycerides >= 150mg/dL and serum HDL cholesterol 4.Waist circumference > 90cm (in males) and > 80cm (in females). 5.Body Mass Index > 25 kg/m2. 6.History of rheumatoid arthritis, osteoarthritis, thyroid disorder, pancreatic impairment and myocardial infarction. 7.History of smoking. 8.Patient requiring change and/or addition of another antihypertensive drug during study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in leptin-adiponectin ratio and homeostasis model assessment â?? insulin resistance (HOMA-IR) at baseline and after 12 weeks of angiotensin converting enzyme inhibitor (ramipril), angiotensin receptor blocker(telmisartan), calcium channel blocker(amlodipine) and thiazide (hydrochlorothiazide) monotherapy within and between each groupTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between leptin-adiponectin ratio and homeostasis model assessment â?? insulin resistance (HOMA-IR) in each group.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr H S Rehan
Lady Hardinge Medical College, Delhi
Outcome results
None listed